Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

Louise C. Druedahl; Timo Minssen; William Nicholson Price II

doi:10.1016/j.vaccine.2021.08.101

Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

Louise C. Druedahl^*, Timo Minssen, William Nicholson Price II

^*Corresponding author for this work

Center for Advanced Studies in Bioscience Innovation Law

Research output: Contribution to journal › Journal article › Research › peer-review

54 Citations (Scopus)

45 Downloads (Pure)

Abstract

This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next.

Volume 39, Issue 42, 8 October 2021, Pages 6291-6295

Original language	English
Journal	Vaccine
Volume	39
Issue number	42
Pages (from-to)	6291 - 6295
ISSN	0264-410X
DOIs	https://doi.org/10.1016/j.vaccine.2021.08.101
Publication status	Published - 8 Oct 2021

Keywords

Faculty of Law
Legal considerations
Pharmaceutical policy
COVID-19
Vaccine
knowledge sharing
empirical legal studies
empirical research

Access to Document

10.1016/j.vaccine.2021.08.101

FulltextFinal published version, 282 KBLicence: CC BY

1 Organisation of and participation in conference
1 Lecture and oral contribution

Accelerating Pharmaceutical Science: innovating and collaborating to fight COVID-19 and future pandemics
Louise C. Druedahl (Invited speaker)
5 Dec 2022
Activity: Talk or presentation types › Lecture and oral contribution
DIA Europe 2022
Louise C. Druedahl (Invited speaker)
30 Mar 2022
Activity: Participating in an event - types › Organisation of and participation in conference

Cite this

@article{b6ee431993db45bc8812c71fe8b865c7,

title = "Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships",

abstract = "This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295",

keywords = "Faculty of Law, Legal considerations, Pharmaceutical policy, COVID-19, Vaccine, knowledge sharing, empirical legal studies, empirical research",

author = "Druedahl, {Louise C.} and Timo Minssen and {Price II}, {William Nicholson}",

year = "2021",

month = oct,

day = "8",

doi = "10.1016/j.vaccine.2021.08.101",

language = "English",

volume = "39",

pages = "6291 -- 6295",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier",

number = "42",

}

TY - JOUR

T1 - Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

AU - Druedahl, Louise C.

AU - Minssen, Timo

AU - Price II, William Nicholson

PY - 2021/10/8

Y1 - 2021/10/8

N2 - This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295

AB - This paper provides an empirical investigation into the types of partnerships that have emerged during the pandemic to develop COVID-19 vaccines and to identify relevant factors that characterize these partnerships. We provide legal and policy considerations to our results that suggest an opportunity for policymakers to help shift the collaborative landscape to increase the potential for knowledge-sharing, the development of fundamental insight, and the adequate production of resulting technological goods, both in this pandemic and the next. Volume 39, Issue 42, 8 October 2021, Pages 6291-6295

KW - Faculty of Law

KW - Legal considerations

KW - Pharmaceutical policy

KW - COVID-19

KW - Vaccine

KW - knowledge sharing

KW - empirical legal studies

KW - empirical research

U2 - 10.1016/j.vaccine.2021.08.101

DO - 10.1016/j.vaccine.2021.08.101

M3 - Journal article

C2 - 34556366

VL - 39

SP - 6291

EP - 6295

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -

Collaboration in Times of Crisis: A Study on COVID-19 Vaccine R&D Partnerships

Abstract

Keywords

Access to Document

Activities

Accelerating Pharmaceutical Science: innovating and collaborating to fight COVID-19 and future pandemics

DIA Europe 2022

Cite this